普乐安联合塞来昔布治疗UPOINT分型T类Ⅲ型慢性前列腺炎的效果观察  

Efficacy of pulean combined with celecoxib on UPOINT phenotype T Ⅲ chronic prostatitis

作　　者：常轲祎 高国政 雷晓航 王芳 CHANG Keyi;GAO Guozheng;LEI Xiaohang;WANG Fang(Reproductive Medical Center,Luoyang Central Hospital Affiliated to Zhengzhou University,Luoyang,Henan 4710o0,China)

机构地区：[1]郑州大学附属洛阳中心医院生殖医学中心,河南洛阳471000

出　　处：《中华实用诊断与治疗杂志》2025年第2期170-173,共4页Journal of Chinese Practical Diagnosis and Therapy

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20200847)。

摘　　要：目的 观察UPOINT分型T类Ⅲ型慢性前列腺炎患者采用普乐安联合塞来昔布治疗后临床症状及炎性因子变化,探讨其治疗效果。方法 2023年4月—2024年3月郑州大学附属洛阳中心医院诊治UPOINT分型T类Ⅲ型慢性前列腺炎患者102例,随机分为观察组和对照组各51例,对照组给予塞来昔布胶囊口服治疗(0.2 g/次,1次/d),观察组在对照组基础上给予普乐安片口服治疗(4片/次,3次/d),2组均连续治疗3周。治疗前、后采用美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评估2组患者临床症状,应用显微镜计数前列腺液白细胞数目,采用流式免疫荧光发光法检测血浆炎性因子[白细胞介素(IL)-10、IL-1β、γ-干扰素(IFN-γ)]水平;比较2组治疗总有效率。结果 治疗后观察组NIH-CPSI评分[16.50(11.00, 23.00)分]、前列腺液白细胞数目[12.50(8.00, 18.00)个]及血浆IL-10、IL-1β、IFN-γ水平[(208.94±16.01)、(0.74±0.19)、(20.90±4.98)ng/L]均低于对照组[20.00(17.75, 23.00)分、15.00(12.00, 18.00)个、(274.29±17.14)ng/L、(0.95±0.21)ng/L、(31.16±5.76)ng/L](Z=-8.614、-8.181,t=5.280~19.890,P均<0.05),2组治疗后NIH-CPSI评分、前列腺液白细胞数目及血浆IL-10、IL-1β、IFN-γ水平均低于治疗前(Z=-8.731~-7.884,t=-25.439~-12.039,P均<0.05),治疗前2组上述指标比较差异均无统计学意义(Z=-0.711、-0.034,t=-0.408~0.304,P均>0.05)。观察组治疗总有效率(94.12%)高于对照组(78.43%)(χ^(2)=5.299,P=0.021)。结论 UPOINT分型T类Ⅲ型慢性前列腺炎患者采用普乐安联合塞来昔布治疗可改善临床症状,减轻炎性反应,疗效良好。Objective To observe the changes of clinical symptoms and inflammatory cytokines in patients with UPOINT phenotype TII chronic prostatitis after treatment with pulean combined with celecoxib and to investigate the therapeutic effect.Methods Totally 102 patients with UPOINT phenotype TII chronic prostatitis were diagnosed and treated in Luoyang Central Hospital Affiliated to Zhengzhou University from April 2023 to March 2024,and were randomly divided into the observation group and the control group,with 51 patients in each group.The control group received oral administration of celecoxib capsules(0.2 g/time,once daily),while the observation group received oral administration of pulean tablets(4 tablets/time,three times daily)on the basis of the treatment in the control group.Both two groups were treated for 3 weeks.Before and after treatment,the National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI)was used to evaluate the clinical symptoms of patients in both groups,the microscope was used to detect white blood cell count in prostatic fluid,the flow immunofluorescence luminescence method was used to detect the levels of serum inflammatory cytokines[interleukin(IL)-10,IL-1β,interferon-(IFN-)].The total effective rate was compared between two groups after treatment.Results The NIH-CPSI score,white blood cell count in prostatic fluid,and the leveis of serum IL-10,IL-1βand IFN-were lower in the observation group[16.50(11.00,23.00),12.50(8.00,18.00),(208.94±16.01)ng/L,(0.74±0.19)ng/L,(20.90±4.98)ng/L]than those in the control group[20.00(17.75,23.00),15.00(12.00,18.00),(274.29±17.14)ng/L,(0.95±0.21)ng/L,(31.16±5.76)ng/L](Z=-8.614,-8.181,t=5.280-19.890;all P values<0.05)after treatment,were lower after treatment than those before treatment in both groups(Z=-8.731 to-7.884,t=-25.439 to-12.039;all P values<0.05),and showed no significant differences between two groups before treatment(Z=-0.71l,-0.034,t=-0.408 to 0.304;all P values>0.05).The total effective rate was higher in the observation gro

关 键 词：慢性前列腺炎 UPOINT分型 普乐安 塞来昔布 炎性因子 

分 类 号：R697.33[医药卫生—泌尿科学]